Versant Ventures’ latest startup is debuting with a partnership with Biogen to make oral macrocycles for immune and inflammatory diseases, a booming area of biopharma investment. Biogen is paying Dayra Therapeutics $50 million upfront as …
Bayer’s stock rallies as next-gen blood thinner beats the odds with Phase 3 win
Bayer’s factor XIa inhibitor slashed the risk of recurrent stroke in a late-stage trial in certain patients, breathing new life into a class of drugs that has suffered a string of high-profile failures. The unexpected …
Stroke data breathes life back into Bayer’s asundexian
Prospects for Bayer’s oral Factor XIa inhibitor asundexian have improved markedly after a phase 3 trial in secondary stroke prevention.
Novo Nordisk’s semaglutide misses in closely-watched Alzheimer’s trials
Novo Nordisk’s bet on semaglutide in Alzheimer’s disease was always a long shot, and like most long shots, it has missed the mark. The GLP-1 agonist failed to delay disease progression in patients in two …
Craig Crews, Mikael Dolsten raise $32M for Quarry Thera
During his daughter’s wedding weekend last year, Mikael Dolsten was running through a flurry of emotions. He was thinking about the marriage, but also about starting a new biotech. The former Pfizer chief scientific officer …
SK Life Science Xcopri ad meets a roadblock with FDA untitled letter
A few months after SK Life Science began rolling out a road trip-themed TV commercial for its antiseizure medication Xcopri, the FDA is attempting to put the brakes on the ad.
J&J abandons Alzheimer’s antibody in setback for tau
Hopes that anti-tau drugs could emerge as treatments for Alzheimer’s have been dented by the failure of a phase 2b trial of J&J’s posdinemab.
Lilly becomes first $1trn+ pharma company
Eli Lilly has become the first pharma group to reach a value of more than $1 trillion, joining a select group populated mainly by tech giants.
Nobel laureate Carolyn Bertozzi to rejoin Lilly board
Carolyn Bertozzi is rejoining the board of Eli Lilly on Dec. 8, the pharma giant disclosed in a Friday evening SEC filing. The 2022 Nobel laureate, who has …
GhostEI-Bench: Do Mobile Agents Resilience to Environmental Injection in Dynamic On-Device Environments?
arXiv:2510.20333v2 Announce Type: replace-cross Abstract: Vision-Language Models (VLMs) are increasingly deployed as autonomous agents to navigate mobile graphical user interfaces (GUIs). Operating in dynamic on-device ecosystems, which include notifications, pop-ups, and inter-app interactions, exposes them to a unique and underexplored threat vector: environmental injection. Unlike prompt-based attacks that manipulate textual instructions, environmental injection corrupts an […]